Managing extensive-stage small cell lung cancer (ES-SCLC) involves not only treating the cancer aggressively but also preventing chemotherapy-induced myelosuppression, a dangerous drop in blood cell counts that can lead to infections like febrile neutropenia.
One common strategy is the use of granulocyte colony-stimulating factor (G-CSF), which helps the body produce more neutrophils. It is often given to patients at higher risk of neutropenia, especially starting from the first cycle of chemotherapy. Another option is Cosela, a newer drug given before chemotherapy. It works differently by protecting bone marrow cells from damage, helping maintain blood cell production throughout treatment.
In one case, a 51-year-old patient developed severe infection shortly after starting chemotherapy and immunotherapy, requiring hospitalization. This highlights how serious these complications can be.
Experts, including Mohamed Mohamed, emphasize early prevention. Current guidelines from the National Comprehensive Cancer Network recommend trilaciclib in this setting, offering a proactive way to reduce risks and improve treatment safety.